OSAI Biopharma

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia
CompanyDrug

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Patronus Biotech Co., Ltd. announced that its three multi‑stage novel U‑VLP malaria vaccine candidates – LYB014, LYB017 and LYB027 – have been approved by the Bellberry Human Research Ethics Committee…

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Suzhou OSAI Biopharma’s L. crispatus Capsule Meets Phase III Endpoints in Bacterial Vaginosis Study